Leaflet IMATINIB CIPLA 100mg capsules


Indicated for: chronic myeloid leukemia; gastrointestinal stromal tumors

Route of administration: oral

Substance: imatinib (tyrosine kinase inhibitor)

ATC: L01EA01 (Antineoplastic and immunomodulating agents | Protein kinase inhibitors | BCR-ABL tyrosine kinase inhibitors)

Precautions:
Fertility warning
Fertility warning

This medicine may affect fertility.

Cytotoxic / special handling
Cytotoxic / special handling

Handle with special care.

Contraception required
Contraception required

Effective contraception is required during treatment.

Contraindicated during breastfeeding
Contraindicated during breastfeeding

Do not use this medicine while breastfeeding.

Contraindicated during pregnancy
Contraindicated during pregnancy

Do not use this medicine during pregnancy.

Avoid grapefruit
Avoid grapefruit

Avoid grapefruit and grapefruit juice.

Hepatotoxicity
Hepatotoxicity

This medicine may affect the liver.

Major drug interactions
Major drug interactions

This medicine may have important interactions with other medicines.

Myelosuppression / agranulocytosis
Myelosuppression / agranulocytosis

This medicine may lower blood cell counts.

Additional monitoring
Additional monitoring

This medicine is subject to additional monitoring.

Requires periodic laboratory tests
Requires periodic laboratory tests

Periodic laboratory tests may be required during treatment.

Severe skin reactions
Severe skin reactions

Stop taking the medicine and seek urgent medical help if a severe rash occurs.

Cardiac risk / QT prolongation / arrhythmias
Cardiac risk / QT prolongation / arrhythmias

This medicine may increase the risk of heart rhythm disturbances.

Imatinib is a tyrosine kinase inhibitor used for the treatment of chronic myeloid leukemia (CML) and other cancers, such as gastrointestinal stromal tumors (GIST). It works by blocking the activity of abnormal proteins that drive cancer cell growth.

The medication is taken orally, usually once daily, as directed by a doctor. It is important to follow the recommended dose to maximize treatment effectiveness.

Side effects may include nausea, vomiting, fluid retention, muscle pain, or fatigue. In rare cases, severe allergic reactions or liver failure may occur.

Imatinib is not recommended for patients with hypersensitivity to this medication or severe liver impairment.

General data about IMATINIB CIPLA 100mg

  • Substance: imatinib
  • Date of last drug list: 01-01-2019
  • Commercial code: W62027003
  • Concentration: 100mg
  • Pharmaceutical form: capsules
  • Quantity: 120
  • Product type: generic
  • Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Pharmaceutical forms available for imatinib

Concentrations available for imatinib

  • 100mg
  • 300mg
  • 400mg
  • 50mg

Other substances similar to imatinib